The average one-year price target for Werewolf Therapeutics (NasdaqGS:HOWL) has been revised to $6.38 / share. This is an ...
Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results